Allergen hybrids - next generation vaccines for Fagales pollen immunotherapy

Clin Exp Allergy. 2014 Mar;44(3):438-49. doi: 10.1111/cea.12250.

Abstract

Background: Trees belonging to the order of Fagales show a distinct geographical distribution. While alder and birch are endemic in the temperate zones of the Northern Hemisphere, hazel, hornbeam and oak prefer a warmer climate. However, specific immunotherapy of Fagales pollen-allergic patients is mainly performed using birch pollen extracts, thus limiting the success of this intervention in birch-free areas.

Objectives: T cells are considered key players in the modification of an allergic immune response during specific immunotherapy (SIT), therefore we thought to combine linear T cell epitope-containing stretches of the five most important Fagales allergens from birch, hazel, alder, oak and hornbeam resulting in a Fagales pollen hybrid (FPH) molecule applicable for SIT.

Methods: A Fagales pollen hybrid was generated by PCR-based recombination of low IgE-binding allergen epitopes. Moreover, a structural-variant FPH4 was calculated by in silico mutagenesis, rendering the protein unable to adopt the Bet v 1-like fold. Both molecules were produced in Escherichia coli, characterized physico-chemically as well as immunologically, and tested in mouse models of allergic sensitization as well as allergy prophylaxis.

Results: Using spectroscopic analyses, both proteins were monomeric, and the secondary structure elements of FPH resemble the ones typical for Bet v 1-like proteins, whereas FPH4 showed increased amounts of unordered structure. Both molecules displayed reduced binding capacities of Bet v 1-specific IgE antibodies. However, in a mouse model, the proteins were able to induce high IgG titres cross-reactive with all parental allergens. Moreover, prophylactic treatment with the hybrid proteins prevented pollen extract-induced allergic lung inflammation in vivo.

Conclusion: The hybrid molecules showed a more efficient uptake and processing by dendritic cells resulting in a modified T cell response. The proteins had a lower IgE-binding capacity compared with the parental allergens, thus the high safety profile and increased efficacy emphasize clinical application for the treatment of Fagales multi-sensitization.

Keywords: Fagales pollen allergy; allergen-specific immunotherapy; birch pollen allergy; hybrid protein; immunomodulation; protein remodelling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allergens / chemistry
  • Allergens / genetics
  • Allergens / immunology*
  • Amino Acid Sequence
  • Animals
  • Cross Reactions / immunology
  • Dendritic Cells / immunology
  • Epitopes / chemistry
  • Epitopes / genetics
  • Epitopes / immunology
  • Epitopes / metabolism
  • Female
  • Humans
  • Immunization
  • Immunization Schedule
  • Immunoglobulin E / immunology
  • Immunoglobulin E / metabolism
  • Immunoglobulin G / immunology
  • Immunotherapy*
  • Mice
  • Molecular Sequence Data
  • Pollen / immunology*
  • Protein Binding / immunology
  • Recombinant Fusion Proteins / chemistry
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology*
  • Rhinitis, Allergic, Seasonal / immunology
  • Rhinitis, Allergic, Seasonal / therapy*
  • Sequence Alignment
  • Spleen / cytology
  • Spleen / immunology
  • Tracheophyta / adverse effects*
  • Vaccines / immunology*

Substances

  • Allergens
  • Epitopes
  • Immunoglobulin G
  • Recombinant Fusion Proteins
  • Vaccines
  • Immunoglobulin E

Associated data

  • GENBANK/EU283857
  • GENBANK/EU283863
  • GENBANK/S50892
  • GENBANK/X70998
  • GENBANK/X77266